Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

MGI: Closing the Cancer Care Gap with the Power of Precision Oncology

This image opens in the lightbox

News provided by

MGI

04 Feb, 2024, 19:53 GMT

Share this article

Share toX

Share this article

Share toX

BERLIN, Feb. 4, 2024 /PRNewswire/ -- According to American Cancer Society, Cancer causes about 1 in every 6 deaths globally, more than AIDS, tuberculosis, and malaria combined. Today, it is the first or second leading cause of death in most countries around the world. Technological advances in genomics have enabled the identification and improved understanding of causal factors and shed light on precision oncology.

Continue Reading
This image opens in the lightbox
image_1
This image opens in the lightbox
image_2

February 4 marks World Cancer Day, an initiative aimed at promoting awareness on cancer as a public health issue and improving access to quality care, screening, early detection, therapy, and palliative care for those affected.

In this new era in precision oncology, researchers like Dr. Marie-Laure Yaspo from ALACRIS Theranostics ("ALACRIS") and Dr. Xuan Gao and Dr.Huan Fang from GenePlus are working towards closing the care gap with evidence-based strategies in cancer control along the care continuum, from prevention to treatment, with help from MGI's cutting-edge life science technologies.

ALACRIS innovates with its advanced tumor-agnostic molecular diagnostic test augmenting tailored treatment options

At ALACRIS Theranostics in Germany, co-founder and Chief Scientific Officer Dr. Marie-Laure Yaspo and her team are committed to provide every cancer patient with the highest standard of care through the Comprehensive Molecular Cancer Analysis (CMTA), a unique molecular diagnostic test designed to identify the best personalized treatment options for each patient, based on high-throughput sequencing of the exome (or genome) and transcriptome of their tumor.

"From past research in cancer genomics projects, we learned how complex and unique the molecular landscape of every tumor can be," said Dr. Yaspo as she recalled her 12+ years in molecular genetics prior to establishing ALACRIS. "Only by collecting comprehensive information on the tumor landscape can we further develop and enhance personalized therapy."

"Every patient is unique, every tumor is different," added Dr. Yaspo. To capture this individuality, the CMTA technology integrates two layers of sequence data, DNA (genome or exome) and RNA (transcriptome), for a comprehensive analysis of the clinically relevant alterations in every tumor. In addition to mutations and chromosome copy number alterations, key features such as gene fusions, overexpressed oncogenes, immune microenvironment, and more provide essential information for the evaluation of the best therapeutic options.

"Starting from a tumor biopsy, the end-to-end Alacris-CMTA® process generates high-throughput sequencing data with MGI's highly accurate and reliable platforms and deploys Alacris's advanced bioinformatics analysis pipelines to deliver a comprehensive, interpreted tumor profiling report," said Dr. Yaspo. "We interprete actionable alterations and match those with drug databases", delivered a concise report guiding oncologists to design personalized therapies. The CMTA® fits the patient's journey, and is particularly well suited for patients with refractory or rare cancers in need of treatment options.  to improve their outcome."

Back in 2022, MGI launched a Customer Experience Center at ALACRIS's Berlin-based facility equipped with MGI's DNBSEQ-G400* sequencer, MGISP-960 automation system and more. Not long after, in 2023, a new DNBSEQ-T7* sequencer was installed to further support the facility's sequencing needs, including pediatric leukemias.

"The time that patients have is limited and precious. The faster we get sequencing samples analyzed, the sooner they can receive personalized treatment," said Dr. Yaspo. "MGI platforms' high flexibility and quick turnaround enable us to provide reliable diagnostics for a large number of patients. Its cost-effectiveness also makes it easier for more people to benefit from affordable and accessible cancer services, thereby contributing to better healthcare."

GenePlus' NGS total solution helps match cancer patients to precise therapy

Meanwhile in China, the team at GenePlus, including Dr. Xuan Gao and Dr. Huan Fang, Assistant Directors of the company's Genomics Institute, has been studying tumor detection and intervention to help clinicians determine the safest and most effective treatment for cancer patients through clinical and scientific research.

"Having witnessed the pain and torment of someone close who suffered from cancer, I was determined to devote myself to cancer precision medicine," said Dr. Gao. "In the 6+ years I've been in the field, high-throughput sequencing technology has rapidly promoted the development of tumor genomics research, giving us a better understanding of the genetic characteristics and molecular mechanisms of tumors, and thereby providing new targets and combination therapy options to alleviate patients' suffering."

Given the inherent complexity and heterogeneity of cancer, as well as its risks of genetic mutation, tumors are constantly evolving, which leads to drug resistance during treatment. Although the stratification of patients has been refined, there still lacks specific, tailor-made therapy options. At the same time, many advances in the field have yet to reach the masses due to high costs and insufficient clinical trial design and data. "MGI's technology plays a critical role in helping us expanding precise tumor tests and genome-driven drug strategies for patients, including those who currently cannot use targeted therapy," added Dr. Gao.

The GenePlus NGS total solution, which includes certified kits, library workshops, genetic sequencers, and the GeneBox informatic platform, facilitates faster, simpler and more reliable cancer sequencing. Benefitting from DNBSEQ's high quality, accuracy and cost-effectiveness, the solution creates a pipeline of tumor precision medication, whole-process case, and pathogen detection. To date, it has been deployed in more than 30 key hospitals in China, where it is applied to the analysis of tumors and pathogens, serving over 550,000 patients in need of accurate diagnosis and treatment.

"Based on MGI's DNBSEQ technology, our solution has low amplification error rate and high data utilization rate, which are crucial for ultra-deep sequencing of low-concentration or low-quality oncology samples," said Dr. Fang. "We leverage this for targeting and immunotherapy guidance in advanced patients and drug sensitivity prediction and cancer minimum residual disease monitoring."

The development of precision oncology has transformed how we approach the cancer care continuum – from prevention to detection, to diagnosis and treatment – for patients who are not only looking to survive but also to do so with an optimal quality of life. Supported by MGI, both CMTA® by ALACRIS and the GenePlus NGS total solution are laying the foundation for precise cancer control and ensuring all patients can enjoy effective, reliable, and affordable care for improved outcomes.

About MGI

MGI Tech Co. Ltd. (or its subsidiaries, together referred to MGI), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation. MGI's mission is to develop and promote advanced life science tools for future healthcare. For more information, please visit the MGI website or connect with us on Twitter, LinkedIn or YouTube.

  • For Research Use Only. Not for use in diagnostic procedures.

Photo - https://mma.prnewswire.com/media/2333769/image_1.jpg
Photo - https://mma.prnewswire.com/media/2333770/image_2.jpg
Logo - https://mma.prnewswire.com/media/2329841/4529193/MGI__Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.